iTeos Therapeutics, Inc. (ITOS)
Largest Insider Buys in Sector
ITOS Stock Price History Chart
ITOS Stock Performance
About iTeos Therapeutics, Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote …
Insider Activity of iTeos Therapeutics, Inc.
Over the last 12 months, insiders at iTeos Therapeutics, Inc. have bought $0 and sold $0 worth of iTeos Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at iTeos Therapeutics, Inc. have bought $39.37M and sold $63.54M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $41,850 was made by Gall Matthew (Chief Financial Officer) on 2023‑10‑12.
List of Insider Buy and Sell Transactions, iTeos Therapeutics, Inc.
| 2023-10-12 | Chief Financial Officer | 5,000 0.0136% | $8.37 | $41,850 | +28.59% | |||
| 2023-08-23 | Sale | 350,000 1.1785% | $16.26 | $5.69M | -17.70% | |||
| 2022-06-08 | Sale | 1,171 0.0033% | $19.51 | $22,846 | -3.14% | |||
| 2022-05-09 | Sale | 337,109 0.7412% | $18.25 | $6.15M | -17.43% | |||
| 2022-04-28 | Sale | 115,000 0.3152% | $27.01 | $3.11M | -29.86% | |||
| 2022-04-18 | Sale | Chief Executive Officer | 11,467 0.0326% | $31.87 | $365,453 | -37.63% | ||
| 2022-03-22 | 20,000 0.0553% | $32.85 | $656,980 | -39.63% | ||||
| 2022-03-21 | Sale | Chief Executive Officer | 5,822 0.0167% | $33.44 | $194,688 | -38.51% | ||
| 2022-03-17 | Sale | 575,201 1.5917% | $35.25 | $20.28M | -43.47% | |||
| 2022-03-11 | Sale | Chief Medical Officer | 3,500 0.0099% | $36.01 | $126,035 | -43.21% | ||
| 2022-03-01 | Sale | Chief Scientific Officer | 10,000 0.0283% | $36.76 | $367,570 | -43.58% | ||
| 2022-02-23 | Sale | Chief Executive Officer | 14,500 0.0414% | $34.34 | $497,905 | -38.35% | ||
| 2022-02-11 | Sale | Chief Medical Officer | 3,500 0.0101% | $35.85 | $125,459 | -40.32% | ||
| 2022-01-25 | Sale | Chief Executive Officer | 14,500 0.0403% | $35.68 | $517,378 | -40.58% | ||
| 2022-01-14 | Sale | Chief Medical Officer | 3,500 0.0098% | $39.32 | $137,614 | -45.75% | ||
| 2022-01-05 | Sale | 10 percent owner | 30,347 0.0856% | $42.03 | $1.28M | -46.62% | ||
| 2022-01-05 | Sale | 10 percent owner | 18,135 0.0512% | $42.03 | $762,214 | -46.62% | ||
| 2022-01-05 | Sale | 10 percent owner | 18,135 0.0512% | $42.03 | $762,214 | -46.62% | ||
| 2022-01-04 | Sale | 10 percent owner | 215,122 0.6156% | $42.66 | $9.18M | -46.05% | ||
| 2022-01-04 | Sale | 10 percent owner | 128,550 0.3679% | $42.66 | $5.48M | -46.05% |
Insider Historical Profitability
| GADICKE ANSBERT | 10 percent owner | 4484728 12.2796% | $9.34 | 1 | 43 | +45.66% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 4417259 12.0949% | $9.34 | 1 | 0 | +45.66% |
| MPM BioVentures 2014, L.P. | 10 percent owner | 2738785 7.499% | $9.34 | 1 | 43 | +45.66% |
| Davis Aaron I. | 2154058 5.898% | $9.34 | 2 | 2 | +3.01% | |
| Boxer Capital, LLC | 1804058 4.9397% | $9.34 | 1 | 3 | +45.66% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $60.25M | 12.23 | 4.42M | 0% | +$0 | 0.06 | |
| BlackRock | $56.13M | 11.39 | 4.11M | -3.45% | -$2M | <0.01 | |
| MPM Asset Management LLC | $37.36M | 7.58 | 2.74M | 0% | +$0 | 15.24 | |
| Ecor1 Capital Llc | $27.27M | 5.54 | 2M | +79.3% | +$12.06M | 0.19 | |
| Boxer Capital, LLC | $24.61M | 4.99 | 1.8M | 0% | +$0 | 0.5 |